Definitive Contract 75F40122C00128
Award Date
9/16/22
Potential Completion Date
9/15/23
Potential Value
$353K
Federal Agency
Food and Drug Administration
Awardee
University Of Wisconsin System
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
165
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $313,326 Firm Fixed Price contract to the University of Wisconsin System, operating through its University of Wisconsin - Madison division. The contract was awarded under a Broad Agency Announcement (BAA) for the "Development of Modernized Acinetobacter Baumannii Susceptibility Guidance for Recommended Antimicrobial Agents Using Pharmacometric Approaches". This contract is not associated with...
This is a $263,016.10 firm fixed price prime contract awarded by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) to Institute For Clinical Pharmacodynamics, Inc., a for-profit minority-owned organization. The contract is for the development of modernized susceptibility guidance for the antibiotics ampicillin and vancomycin for Enterococcus species using pharmacometric approaches. The contract has an ultimate completion date of March 29, 2025. The...
This federal contract award, valued at $399,991.00, was issued by the U.S. Food and Drug Administration (FDA) to Midwestern University, a private non-profit educational institution, to develop and validate population pharmacokinetic models for beta-lactam antibiotics used in Continuous Renal Replacement Therapy (CRRT) for patients with hospital-acquired pneumonia. The contract was awarded under a Broad Agency Announcement (BAA) that sought research and development proposals to advance regulatory...
The Food and Drug Administration awarded a $307,205 cost-no-fee contract to The Johns Hopkins University under Broad Agency Announcement PMWP#173 to evaluate the impact of extended-infusion beta-lactam administration strategies on improving clinical outcomes and reducing the subsequent emergence of antimicrobial resistance. The contract was awarded through the Department of Health and Human Services' Fiscal Year 2021 FDA Broad Agency Announcement for Advanced Research and Development of...
This $291,142 firm fixed price prime contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to the Institute For Clinical Pharmacodynamics, Inc. to conduct research on updating susceptibility guidance for the oral antibiotics sulfamethoxazole-trimethoprim. The contract supports the agency's efforts to develop modernized susceptibility guidance using pharmacometric approaches. No set-aside designation was used for this award. The Institute For Clinical...
The U.S. Food and Drug Administration (FDA) awarded a $400,000.00 firm-fixed price contract to the Regents of the University of Michigan, Office of Research and Sponsored Projects (University of Michigan) to advance the science of in vitro, animal model, pharmacokinetic studies, and/or real-world evidence studies to facilitate drug development, including studies focused on antimicrobial resistance and drug development. This contract has a period of performance through March 31, 2026. The...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $498,853.60 firm-fixed-price delivery order contract to the University of Wisconsin System, through its University of Wisconsin - Madison division doing business as Research and Sponsored Programs. This order is part of the broader Safety and Healthcare Epidemiology Prevention Research Development 2016 (SHEPheRD 2016) indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract has a...
This federal contract award was issued by the Food and Drug Administration (FDA) to The Medical College of Wisconsin, Inc. (MCW), a private medical school and research institution, for $198,354.17. The contract supports research services related to Bayesian modeling techniques for clinical trials with matched and interval-censored data. This work is being conducted pursuant to the FDA's Broad Agency Announcement for Advanced Regulatory Science, which seeks to modernize various areas of...
This definitive cost-no-fee contract was awarded by the Department of Health and Human Services Food and Drug Administration (HHS FDA) to Monash University. The contract value is $399,988 to support a study titled "Bridging the Gap Between Urinary Tract Infection Pharmacokinetic/Pharmacodynamic In Vitro Models and the Optimization of Antibiotic Selection, Dosing Strategies, Clinical Breakpoints, and Novel Drug Development." This award was made under the FY23 FDA Broad Agency...
This is a $1,913,800.00 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to the University of Wisconsin System for a project titled "FY 21 BAA TOPIC 8 - WISCONSIN-MADISON". There is no set-aside designation for this award. The contract has an ultimate completion date of May 16, 2023. The University of Wisconsin System, through its University of Wisconsin - Madison division operating as Research and Sponsored Programs, will be the prime...